Alzheimer's disease (AD) will become a public health crisis within the next 2-3 decades if left unchecked. There are no proven treatments that delay the onset or prevent the progression of AD, although several promising candidates are being developed. During the development of these therapies, it will be very important to have biomarkers that can identify individuals at high risk for AD in eariiest clinical stages in order to target them for clinical trials of disease-modifying therapies and to monitor therapy success. Clinicopathologic evidence suggests that AD pathology (particularly the buildup of amyloid plaques) begins 10-20 years before the onset of cognitive symptoms. The earliest clinical symptoms of AD are accompanied by, and likely due to, neuronal and synaptic dysfunction and/or cell death. Thus, it will be critical to identify individuals with """"""""preclinical"""""""" and very early stage symptomatic AD, prior to marked clinical symptoms and neuron loss, so new therapies will have the greatest chance to preserve normal brain function. The Adult Children Study (ACS) Biomarker Core was initially funded as a competitive supplement to the ACS PPG in April 2008. The Core's mission is to facilitate and support antecedent AD biomarkers research by providing the necessary infrastructure for the collection, storage, and dissemination of fluid (CSF and plasma) samples (and associated data) for our own research at Washington University and that of the greater AD scientific community. Since inception of the Core, our productivity has roughly doubled (as defined by the number of CSF and plasma samples collected, the number of samples disseminated to investigators, and the number of papers using our samples that have been published in peer-reviewed journals). Thus, in the present renewal application, we propose to build upon our success and propose the following aims:
Aim 1 : Maintain and grow a repository of fasted CSF and plasma samples for present and future aging and AD biomarker studies.
Aim 2 : Coordinate the distribution of CSF and plasma samples to qualified investigators.
Aim 3 : Compare the values obtained for CSF Ap42, tau and ptauiei in Project 2 as a function of assay (Innotest vs. xMAP) and plasma Ap species (APi^o, APx-40, APi.42. APx^2) as a function of fasting state.
There are currently no effective treatments that will prevent Alzheimer's disease, halt its progression or delay its onset, although several therapeutic approaches are being developed and tested in clinical trials. Parallel efforts are being channeled into developing biomarkers that would aid in disease diagnosis and prognosis and assessing disease risk. Together these combined endeavors have the potential to provide physicians the tools to effectively diagnose and treat the disease, preferably everi before the onset of cognitive decline.
| Strain, Jeremy F; Smith, Robert X; Beaumont, Helen et al. (2018) Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology 91:e313-e318 |
| Li, Zeran; Del-Aguila, Jorge L; Dube, Umber et al. (2018) Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10:43 |
| Schindler, Suzanne E; Sutphen, Courtney L; Teunissen, Charlotte et al. (2018) Upward drift in cerebrospinal fluid amyloid ? 42 assay values for more than 10 years. Alzheimers Dement 14:62-70 |
| Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98:861-864 |
| Babulal, Ganesh M; Chen, Suzie; Williams, Monique M et al. (2018) Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. J Alzheimers Dis 66:1213-1221 |
| Millar, Peter R; Balota, David A; Bishara, Anthony J et al. (2018) Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease. Mem Cognit 46:1058-1075 |
| Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98 |
| Vlassenko, Andrei G; Gordon, Brian A; Goyal, Manu S et al. (2018) Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiol Aging 67:95-98 |
| Roe, Catherine M; Babulal, Ganesh M; Stout, Sarah H et al. (2018) Using the A/T/N Framework to Examine Driving in Preclinical AD. Geriatrics (Basel) 3: |
| Stout, Sarah H; Babulal, Ganesh M; Ma, Chunyu et al. (2018) Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimers Dement 14:610-616 |
Showing the most recent 10 out of 352 publications
